Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
DRTS · Why this verdict
Why Alpha Tau Medical (DRTS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock is technically overbought (RSI 82) with rising volume (OBV) and trading above its 200-day moving average, reflecting a strong recent price run. Momentum breakdown | RSI should cool from overbought levels while price holds above the 200-day MA, confirming a healthy consolidation rather than a reversal. | →Stable |
| CounterRSI 82 combined with a V8 price target already reached (-6.6% implied downside) suggests the move may be exhausted rather than the start of a sustainable uptrend. | ||
The company has missed earnings estimates in all of the last 4 quarters (0 beats/4 misses, average surprise -39.7%), reflecting a persistent execution/guidance gap. Catalyst breakdown | The company should post at least one earnings beat within the next 2 reporting quarters to break the miss streak. | →Stable |
| CounterPre-revenue clinical-stage biotechs routinely miss consensus EPS estimates because Street models are poorly calibrated to burn rate, so the miss streak may carry less signal than for an operating company. | ||
The V8 model's price target has already been reached, leaving negative asymmetry (-0.44 ratio) and limited further upside at current levels. Bear case | The asymmetry ratio should turn positive (above 1.5) as either price pulls back or the target is revised higher on new data. | →Stable |
| CounterBinary catalysts common in biotech, such as trial readouts, can reset price targets sharply higher overnight, independent of the current asymmetry calculation. | ||
Insiders have been net sellers ($739K, 0.062% of market cap), a modest but negative signal on insider sentiment. Insider breakdown | Insider activity should shift back to net-neutral or net-buying within the next two quarters if management confidence is intact. | →Stable |
| CounterThe selling is characterized as modest and low-materiality, likely reflecting routine diversification such as pre-scheduled selling plans (Rule 10b5-1) rather than a meaningful negative signal. | ||
The stock is technically overbought (RSI 82) with rising volume (OBV) and trading above its 200-day moving average, reflecting a strong recent price run.
→StableMomentum breakdown
- Expectation
- RSI should cool from overbought levels while price holds above the 200-day MA, confirming a healthy consolidation rather than a reversal.
CounterRSI 82 combined with a V8 price target already reached (-6.6% implied downside) suggests the move may be exhausted rather than the start of a sustainable uptrend.
The company has missed earnings estimates in all of the last 4 quarters (0 beats/4 misses, average surprise -39.7%), reflecting a persistent execution/guidance gap.
→StableCatalyst breakdown
- Expectation
- The company should post at least one earnings beat within the next 2 reporting quarters to break the miss streak.
CounterPre-revenue clinical-stage biotechs routinely miss consensus EPS estimates because Street models are poorly calibrated to burn rate, so the miss streak may carry less signal than for an operating company.
The V8 model's price target has already been reached, leaving negative asymmetry (-0.44 ratio) and limited further upside at current levels.
→StableBear case
- Expectation
- The asymmetry ratio should turn positive (above 1.5) as either price pulls back or the target is revised higher on new data.
CounterBinary catalysts common in biotech, such as trial readouts, can reset price targets sharply higher overnight, independent of the current asymmetry calculation.
Insiders have been net sellers ($739K, 0.062% of market cap), a modest but negative signal on insider sentiment.
→StableInsider breakdown
- Expectation
- Insider activity should shift back to net-neutral or net-buying within the next two quarters if management confidence is intact.
CounterThe selling is characterized as modest and low-materiality, likely reflecting routine diversification such as pre-scheduled selling plans (Rule 10b5-1) rather than a meaningful negative signal.
TrendMatrix Research · core thesis
Engine thesis — one sentence
DRTS is technically overbought after a strong run that has already reached its V8 price target, compounded by a four-quarter earnings miss streak and modest insider selling, leaving negative risk/reward asymmetry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.2 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 9.3 |
- ▸Overbought (RSI 82)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.7 |
| erm sentiment | 5.0 |
Insider
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.9 |
| notable moves | 7.0 |
- ▸Modest insider selling — $739,170 (0.062% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.2 |
| growth rank | 5.0 |
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.0 |
| 52w position | 9.2 |
| gap | 5.0 |
Risk (lower is worse)
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.3 |
| days to cover | 8.9 |
| volatility | 0.0 |
| put call | 9.6 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 6.3 |
| debt equity | 9.2 |
- ▸High IV: 101%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/4M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:8.4>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.6=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.60
Upside
-9.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 8.4 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.6=NEGATIVE.
The strongest dimensions are Momentum at 8.4, Risk (lower is worse) at 6.2, and Sentiment at 5.2; the weakest are Quality at 1.8, Catalyst at 2.5, and Peer rank at 2.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.60 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Overbought Momentum Run
Trip ifRSI falls below 30 within the next month, indicating a sharp reversal from overbought levels.
- P2Four Quarter Earnings Miss Streak
Trip ifThe company's consecutive earnings-miss streak exceeds 4 quarters with a 5th consecutive miss.
- P3Negative Risk Reward Asymmetry
Trip ifAsymmetry ratio rises above 1.5 from the current -0.44.
- P4Modest Insider Selling
Trip ifInsider selling as a percentage of market cap exceeds 0.5% within the next quarter.